Novo Nordisk's STEP Young Phase 3 trial showed its obesity drug, semaglutide (Wegovy), significantly reduced BMI in children aged 6-12, with 40.4% achieving non-obese status compared to 0% in the placebo group. This positive clinical trial result expands the potential market for Wegovy and reinforces Novo Nordisk's leadership in the obesity treatment space, despite a slight premarket dip in share price.
Novo Nordisk announced positive topline results from its STEP Young Phase 3 clinical trial for semaglutide (Wegovy) in children aged 6-12 with obesity. The study met its primary endpoint, demonstrating a significantly higher reduction in BMI, with over 40% of treated children no longer classified as obese. This is a significant development as it addresses a growing public health concern with limited treatment options, potentially opening up a new and substantial market segment for Novo Nordisk. While the stock saw a slight premarket dip, likely due to broader market sentiment or profit-taking, the long-term implications are positive for NVO, solidifying its position in the lucrative obesity drug market. Competitors in the GLP-1 space will be watching closely.